P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies

Iris Martinez-Quetglas; Roser Pinyol; Daniel Dauch; Anna Portela; Judit Peix; Mónica Higuera; Jessica Zucman‐Rossi; Manel Esteller; Vincenzo Mazzaferro; Lars Zender; Josep M. Llovet

doi:10.1016/s0168-8278(15)30481-5

Related publications

Article2014

466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

I.M. Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Alberto Villanueva, Judit Peix, María Ángeles Moreno de la Higuera, Agrin Moeini, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

European Journal of Cancer

Article2016

Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Silvana Bonilla, Anna Portela, Leonardo Rodríguez‐Carunchio, María A. Solé, A. Villanueva, Manel Esteller, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2017

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

I.M. Quetglas, Daniela Sia, Jiao Yan, Moe Maeda, M. Castro, Manel Esteller, Josep M. Llovet

Journal of Hepatology

Letter2003

HCC surveillance: Who is the target population?

Jordi Bruix, Josep M. Llovet

Hepatology

Article2019

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Mohsen Malehmir, Dominik Pfister, Suchira Gallage, Marta Szydlowska, Donato Inverso, Elena Kotsiliti, Valentina Leone, Moritz Peiseler, Bas G. J. Surewaard, Dominik Rath, Adnan Ali, Monika Wolf, Hannah K. Drescher, Marc E. Healy, Daniel Dauch, Daniela C. Kroy, Oliver Krenkel, Marlene Kohlhepp, Thomas Engleitner, Alexander Olkus, Tjeerd Sijmonsma, Julia Volz, Carsten Deppermann, David Stegner,